ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1689

Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada
Abstract Number: 1690

Henoch-Schönlein Purpura Nephritis: Different Histological Classifications, but Which One Is Most Strongly Associated to the Outcome of the Disease? Pilot Study of the Paediatric Rheumatology European Society Vasculitis Working Party
Abstract Number: 1691

Applied Geostatistics in Pediatric Rheumatology – Spatial Clustering of IgA Vasculitis
Abstract Number: 1692

Poor Physical Activity Levels and Cardiorespiratory Fitness Among Patients with Childhood-Onset Takayasu Arteritis in Remission
Abstract Number: 1693

Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
Abstract Number: 1694

Risk Factors Associated with Pneumocystis Jirovecii Pneumonia in Juvenile Myositis in North America
Abstract Number: 1695

Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Dermatomyositis: Focus on the Lung
Abstract Number: 1696

Measuring Quality Improvement from CME Participants: Results from the RAPID® CME Initiative
Abstract Number: 1697

Immune Related Adverse Events from Checkpoint Inhibitor Therapy: Survey of Hospitalists’ Awareness and Experiences
Abstract Number: 1698

Polyarthritis Workup in Primary Care Setting : How Are We Doing?
Abstract Number: 1699

Training Residents to ‘Choose Wisely’ When Testing for Antinuclear Antibodies
Abstract Number: 1700

Curricular Implementation of the Rheumatic Disease Patient Expert Program: The Students’ Perspective
Abstract Number: 1701

Development and Validity Evidence for a Tool to Assess the Performance of Shoulder Injections
Abstract Number: 1702

RA-Related Knowledge and Skills of Rheumatology Fellows Among 20 US Academic Institutions
Abstract Number: 1703

Gender Equity in Academic Rheumatology – Is There a Gender Gap at European Rheumatology Congresses?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].